While the ebb and flow of mpox outbreaks may have taken a toll on Bavarian Nordic’s 2024 sales performance, the year also validated, in large part, the travel vaccines business the Danish company has been building out since the start
read more
Cohort expansion phase commences with promising results More: SECuRE trial pre-chemo participants experience PSA level drops Source: News
read more
Innovative digital transformation leads to significant improvements More: Rotherham NHS Foundation Trust enhances patient engagement Source: News
read moreA new survey commissioned by Leo Pharma confirms that there’s plenty of room in the market for its chronic hand eczema treatment Anzupgo, which is currently under review by the FDA. More: Leo Pharma, awaiting FDA approval decision, finds dermatologists
read moreThe move follows a similar price cut by Eli Lilly as both GLP-1 drugmakers attempt to fend off cheaper compounded versions of their popular obesity meds. More: Novo counters compounders with direct access channel for Wegovy, price cut for self-paying
read moreAfter Bayer’s blood thinner Xarelto saw a sales decline of 600 million euros ($646 million) in 2024 because of generic competition, the company is projecting a sharper fall of between 1 billion and 1.5 billion euros in 2025. More: As
read more© 1994 - 2026 B.M. Pharmaceuticals